These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9409497)

  • 21. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
    Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
    Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
    [No Abstract]   [Full Text] [Related]  

  • 22. Identifying and overcoming barriers to prophylaxis in the management of haemophilia.
    Petrini P
    Haemophilia; 2007 Sep; 13 Suppl 2():16-22. PubMed ID: 17685919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Haemophilia].
    Loomans JI; Lock J; Peters M; Leebeek FW; Cnossen MH; Fijnvandraat K
    Ned Tijdschr Geneeskd; 2014; 158():A7357. PubMed ID: 25351381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The natural history of mild haemophilia: a 30-year single centre experience.
    Tagliaferri A; Di Perna C; Riccardi F; Pattacini C; Rivolta GF; Franchini M
    Haemophilia; 2012 Mar; 18(2):166-74. PubMed ID: 21771207
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of haemophilia treatment: a cross-national assessment.
    Lippert B; Berger K; Berntorp E; Giangrande P; van den Berg M; Schramm W; Siebert U;
    Blood Coagul Fibrinolysis; 2005 Oct; 16(7):477-85. PubMed ID: 16175006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health economics of treating haemophilia A with inhibitors.
    Knight C
    Haemophilia; 2005 Nov; 11 Suppl 1():11-7. PubMed ID: 16219044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progress in the clinical management of haemophilia.
    Bloom AL
    Thromb Haemost; 1991 Jul; 66(1):166-77. PubMed ID: 1926047
    [No Abstract]   [Full Text] [Related]  

  • 28. A synopsis of current haemophilia care in Hong Kong.
    Au WY; Lee V; Kho B; Ling AS; Chan D; Chan EY; Chan GC; Cheung WW; Lau CW; Lee CY; Li RC; Li CK; Lin SY; Mak V; Sun L; Wong KH; Wong R; Yau J; Yuen HL
    Hong Kong Med J; 2011 Jun; 17(3):189-94. PubMed ID: 21636866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New therapeutic products and difficult decisions. The case of recombinant factor VIII in the management of haemophilia A.
    Green C; Akehurst R
    J Public Health Med; 1998 Jun; 20(2):137-8. PubMed ID: 9675729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chronic arthropathy management in haemophilia: assessing the impact of a new model of care.
    d'Young I; Young L; Brasser M; Ockelford P
    N Z Med J; 2012 Apr; 125(1353):161-3. PubMed ID: 22522280
    [No Abstract]   [Full Text] [Related]  

  • 31. Optimal haemophilia care versus the reality.
    Bolton-Maggs PH
    Br J Haematol; 2006 Mar; 132(6):671-82. PubMed ID: 16487168
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factor VIII/factor IX prophylaxis for severe hemophilia.
    Carcao M; Srivastava A
    Semin Hematol; 2016 Jan; 53(1):3-9. PubMed ID: 26805901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
    Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
    Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A.
    Globe DR; Cunningham WE; Andersen R; Dietrich SL; Curtis RG; Parish KL; Miller RT; Sanders NL; Kominski G;
    Haemophilia; 2003 May; 9(3):325-31. PubMed ID: 12694525
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Laboratory measurement of factor replacement therapies in the treatment of congenital haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Gray E; Kitchen S; Bowyer A; Chowdary P; Jenkins PV; Murphy P; Platton S; Riddell A; Lester W
    Haemophilia; 2020 Jan; 26(1):6-16. PubMed ID: 31846168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy.
    Giampaolo A; Abbonizio F; Puopolo M; Arcieri R; Mannucci PM; ; Hassan HJ; Accorsi A; Ettorre PC; Schiavoni M; Palareti G; Rodorigo G; Valdré L; Amaddii G; Billio A; Notarangelo L; Iannacaro P; Muleo P; Biasioli C; Rossi V; Alatri A; Testa S; Vincenzi D; Scapoli G; Morfini M; Molinari AC; Lapecorella M; Mariani G; Baudo F; Caimi MT; Federici AB; Gringeri A; Mannucci PM; Santagostino E; Marietta M; Coppola A; Di Minno G; Perricone C; Schiavulli M; Miraglia E; Rocino A; Zanon E; Gagliano F; Mancuso G; Siragusa S; Rivolta F; Tagliaferri A; Gamba G; Iorio A; Oliovecchio E; Dragani A; Arbasi MC; Albertini P; Mancino A; Lombardo VT; Latella C; D'Incà M; Landolfi Raffaele ; Biondo Francesca ; Mazzucconi MG; Santoro Cristina ; Mameli AL; Piseddu G; Schinco PC; Messina M; Rossetti G; Barillari G; Feola G; Franchini M; Gandini G; Castaman G; Rodeghiero F
    Transfus Med; 2011 Aug; 21(4):280-4. PubMed ID: 21733006
    [No Abstract]   [Full Text] [Related]  

  • 39. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Management of hemophilia].
    Laurian Y
    Rev Prat; 1989 Dec; 39(30):2669-73. PubMed ID: 2515580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.